Ajinomoto Co., Ltd.

Chiori Ijichi

Takashi Yamamoto

Yuzuru Eto

Koji Ohsumi

Naoyuki Fukuchi

Keiji Iwasaki

Akira Chiba

Kazutami Sakamoto

Sayaka Asari

Yoshinobu Takino

Satoshi Iwayama

Koichi Fujita

Itsuya Tanabe

Misato Noguchi

Eiji Shiojiri

Hiromi Chujou

Yuka Kataba

Naoko Oomuta

Yuko Iida

Azole compounds represented by formula I: wherein ring A is isoxazole and the like, R1 is a substituted or unsubstituted aryl group and the like, R2 is a hydrogen atom and the like, and R3 is a substituted or unsubstituted alkyl group and the like, and pharmaceutically acceptable salts thereof inhibit the physiological activity of lysophosphatidic acid (LPA), and are useful as for the prophylaxis or treatment of diseases in which inhibition of the physiological activity of LPA is useful for the prophylaxis or treatment thereof, such as diseases involving the LPA receptor.

Azole compound

In the present specification is disclosed a melanocyte-stimulating hormone inhibitory composition which comprises, as the active ingredient, a di- or tripeptide derivative having a certain naphthyl group or the salts thereof, or a melanocyte-stimulating hormone inhibitory compound having a 50% inhibitory concentration of cAMP production (IC50) of 100 nM or less, which composition can prevent pigmentation, or can prevent, improve or recover from immune abnormality or immunodeficiency, or regulate body weight by appetite control, and also can be used as cosmetics or external preparations for the skin, and in addition, can be produced easily, and are excellent in the stability during storage.

Melanocyte-stimulating hormone inhibitors

Growing community of inventors

Kawasaki, Japan

Chiori Ijichi